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Abstract
Background: Cytomegalovirus (CMV) reactivation in critically ill patients is a well-recognized phenomenon with an
incidence as high as 71 %. A number of studies have investigated the association between CMV reactivation and
outcomes in critically ill patients with conflicting results. We propose to conduct a systematic review and meta-
analysis to determine the impact of CMV reactivation on patient-centered outcomes and measures of health
resource utilization in immunocompetent critically ill patients.
Methods: In consultation with a research librarian, a search strategy will be developed and electronic databases (i.e.,
Ovid MEDLINE, Ovid EMBASE, and the Cochrane Library including the Cochrane Database of Systematic Reviews, the
Cochrane Central Register of Controlled Trials (CENTRAL)) will be searched for original studies. Selected grey literature
sources will be hand-searched. Search themes will include cytomegalovirus, intensive care unit, and sepsis. Citation
screening, selection, quality assessment, and data abstraction will be performed in duplicate. Pooled effect estimates of
the impact of CMV reactivation on selected patient-centered outcomes and measures of health resource utilization will
be described.
Discussion: This systematic review aims to explore the impact of CMV reactivation on patient-centered outcomes and
health resource utilization in immunocompetent critically ill patients. Our results will help to better define the burden
of disease associated with CMV reactivation. Indeed, evidence to date suggests increased mortality in this patient
population. However, the relationship between CMV reactivation and health resource utilization remains less clear.
Based on our results, future study on the impact of CMV treatment or prophylaxis on outcomes (including those other
than mortality) may be warranted.
Systematic review registration: PROSPERO CRD42016035446
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Background
It is estimated that 40 to 100 % of immunocompetent
adults are cytomegalovirus (CMV) seropositive globally
[1,2]. In Canada, seroprevalence ranges between 60 and
80 % [2]. Most primary infections occur in childhood
and are subclinical or present with non-specific
symptoms. CMV subsequently remains latent in mono-
cytes and macrophages [3, 4]. This state of latency allows
CMV to reactivate when host defenses become compro-
mised, such as in critical illness. CMV reactivation in
critically ill patients is well-recognized with as high as
71 % incidence [5]. The consequences of CMV reactiva-
tion in immunocompromised patient populations, such
as solid organ transplantation, have been well described
[6]. However, the clinical significance in immunocompe-
tent patients remains controversial. Some postulate viral
pathogenesis by direct cytopathic effect (tissue-invasive
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disease) [5, 7–9], by an over-response of the immune
system [5, 10] or by inactivation of host defenses allow-
ing opportunistic pathogens to establish infection [5, 11,
12]. Others have suggested that CMV reactivation is
only a marker of illness severity [5].
Since the 1990s, a number of studies have investigated
the association between CMV reactivation and outcomes
in critically ill patients. In 1990, Domart et al. examined
patients with mediastinitis following cardiac surgery who
were CMV infected, defined by blood and/or urine viral
cultures. They showed a significant increase in mortality
and hospital length of stay compared with CMV-
uninfected patients [13]. Thereafter, other studies have
also reported increased mortality [14, 15], increased dur-
ation of mechanical ventilation [11, 12], increased length
of intensive care unit (ICU) stay [16, 17], and increased
incidence of nosocomial infections [18]. Contrasting this
data, Heininger et al. failed to demonstrate a difference
in in-hospital mortality in patients with CMV DNAemia
[19]. More recently, Frantzeskaki et al. came to the same
conclusion [20].
With a growing number of studies examining the
impact of CMV reactivation on outcomes and dis-
crepancies in the available data, systematic reviews
and meta-analyses have been previously undertaken.
In 2009, Osawa et al. conducted the first systematic
review on the subject, which included 13 studies.
Four studies reported data on duration of mechanical
ventilation—all of which showed a statistically signifi-
cant negative effect of CMV reactivation on this out-
come. No pooled estimate was available, as they did
not perform a meta-analysis. All but two of the in-
cluded studies reporting death showed no difference
between CMV positive and negative patients and
mortality [21]. Conversely, Kalil et al. published a
meta-analysis the same year including eight studies
and 633 patients showing a twofold increase in the
odds ratio of death with CMV infection. There was
however no data on other clinical outcomes [22].
These authors updated their results after Heininger
et al. published the study mentioned above showing
no difference in mortality [19]. The effect of CMV
infection on mortality remained significant [23].
Finally, Coisel et al. performed a prospective study on
the prognosis of CMV-infected mechanically venti-
lated patients in which they included a meta-analysis
demonstrating a positive association between CMV
antigenemia and mortality [24]. Since the publication
of the last meta-analysis, at least four additional stud-
ies have been published on this topic with varying
results [20, 25–27].
Considering the availability of new evidence and the
absence of meta-analyses examining important outcomes
such as mechanical ventilation duration, ICU length of
stay, or incidence of nosocomial infection, we propose to
conduct a systematic review and meta-analysis to deter-
mine the impact of CMV reactivation on various clinical
outcomes in immunocompetent critically ill patients.
Objectives
The aim of our systematic review is to determine the im-
pact of CMV reactivation (defined by either pp65 CMV
antigenemia or blood/plasma CMV DNAemia detected
by quantitative nucleic acid testing [NAT]) compared to
no reactivation on patient-centered outcomes (including
mortality, duration of mechanical ventilation, nosoco-
mial infection) or health services utilization (ICU length




A systematic review will be performed using guidelines
from The Cochrane Collaboration and Center for Re-
views and Dissemination and described according to
PRISMA-P guidelines (available at: http://www.systema-
ticreviewsjournal.com/content/4/1/1) (see Additional file
1) [28].
Study registration
In accordance with PRISMA-P guidelines, our system-
atic review will be registered with the International
Prospective Register of Systematic Reviews (PROSPERO)
(www.crd.york.ac.uk/prospero; registration number
CRD42016035446).
Criteria for considering studies for this review
Inclusion criteria:
1. Population: We will include studies of adults
[>18 years of age] who are immunocompetent [i.e.,
we will specifically exclude solid organ or bone
marrow transplant patients, those with advanced
HIV/AIDS, or those receiving cytotoxic therapies]
admitted to any type of ICU for any cause. Patients
with documented CMV tissue invasive disease will
also be excluded.
2. Intervention: Critically ill patients with CMV
reactivation, defined by either pp65 CMV
antigenemia or blood/plasma DNAemia, will be
compared to those without reactivation.
3. Outcomes: We will examine the impact of CMV
reactivation on at least one patient-centered out-
come or measure of health resource utilization.
4. Design: We will include observational studies
(prospective and retrospective) as well as
randomized trials. We will exclude case reports and
case series.
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Exclusion criteria
Studies will be excluded if they do not fulfill all of the in-
clusion criteria; if they are published in a language other
than English or French, use serology to define CMV
reactivation, or include immunocompromised patients
(as defined above).
Search methods for identification of studies
PROSPERO (http://www.crd.york.ac.uk/prospero) was
searched for any registered systematic reviews on this
topic (November 30, 2015).
The search strategy was developed in consultation
with an expert librarian/information specialist at the
Alberta Research Centre for Health Evidence (ARCHE)
at the University of Alberta and has undergone subse-
quent peer-review by a second specialized librarian using
the Peer Review of Electronic Search Strategies checklist
[29]. The information specialist will search electronic
databases: Ovid MEDLINE, Ovid EMBASE, and the
Cochrane Library including the Cochrane Database of
Systematic Reviews, the Cochrane Central Register of
Controlled Trials (CENTRAL) for three domains:
cytomegalovirus, intensive care unit, and sepsis. Data-
base search results will be restricted to papers published
in English or French language and published after 1990
for screening.
Appropriate truncation and wildcards will be used in
the search to account for plurals and/or variations in the
spelling of search terms (see Additional file 2 for ex-
ample of the search strategy in Medline). Bibliographic
records will be exported to EndNote X7 (Thomson Reu-
ters, Philadelphia, Pennsylvania) for screening. Add-
itional sources will be included in the search strategy.
The cited and citing references of selected key studies
will be searched for relevant articles. Grey literature
sources will be searched. We will identify and search
relevant conference proceedings from the past 2 years:
Infectious Diseases Society of America (IDSA) IDWeek,
Canadian Association for Clinical Medical Microbiology
and Infectious Diseases-Association of Medical Micro-
biology and Infectious Diseases Canada (CACMID-
AMMI) Annual Meeting, European Society of Clinical
Microbiology and Infectious Diseases (ESCMID) Annual
Congress, Society of Critical Care Medicine Annual Con-
gress, International Symposium on Intensive Care and
Emergency Medicine. We will also search the trial regis-
try at www.clinicaltrials.gov for trials conducted during
the past 2 years.
Study selection
Potentially eligible articles will be identified by two
authors after independent review of the titles and ab-
stracts of all articles identified by the search. The full
text of all articles deemed potentially relevant will be
independently reviewed, again by the two authors, for
inclusion using pre-defined eligibility criteria. Any dis-
agreements that arise will be resolved through discussion
and/or arbitration by the senior author. Inter-rater
agreement will be calculated.
Data extraction
Data will be abstracted from relevant studies using a stan-
dardized electronic data collection form (Additional file 3).
Data extracted will include publication-related information,
patient-related information (demographic characteristics
and medical comorbidities, design, and quality assessments
of the included studies, inclusion, and exclusion criteria),
and the method of CMV detection. Patient-related out-
comes and health service use will also be collected. This
form will undergo pilot testing. Abstraction will be per-
formed in duplicate by the same two authors. Any disagree-
ments that arise will be resolved through discussion or
arbitration by the senior author. The authors of the re-
trieved studies and/or documents will be contacted for fur-
ther information as necessary.
Study methodological quality will be rated using the
Newcastle-Ottawa Scale (NOS) [30] for observational stud-
ies and the Cochrane Collaboration’s tool [31] for trials.
Outcomes
The primary outcome of our study will be mortality
(however defined in the included studies). Secondary
outcomes will be mechanical ventilation duration, noso-
comial infections, need for renal replacement therapy,
ICU length of stay, and hospital length of stay.
Analysis
Pooled effect estimates of the impact of CMV reactiva-
tion on patient-centered outcomes and health service
use will be reported. We will assess and quantify statis-
tical heterogeneity for each pooled summary estimate
using Cochran’s Q statistic and the I2 statistic, respect-
ively [32]. Pooled analysis will be performed using ran-
dom effects models and reported as odds ratios with
95 % confidence intervals for categorical variables and
weighted mean differences with 95 % confidence inter-
vals for continuous variables, respectively. We expect to
see heterogeneity as a result of different CMV detection
methods, varied study designs, and due to the evolution
in ICU care over time. To address this, we plan to per-
form a number of pre-defined sensitivity analyses ac-
cording to the following variables: study design
(observational vs. RCT), year of study (before or after
2005), and studies including only mechanically ventilated
patients. Publication bias will be assessed using Egger’s
regression models and visualized using funnel plots [33].
All analyses will be performed using RevMan statistical
software.
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Expected limitations
Based on screening of the literature, we expect some de-
gree of heterogeneity in our study populations and in
the frequency of CMV monitoring. The latter may affect
our ability to detect CMV reactivation. Heterogeneity
may limit the interpretation of our results.
Inter-laboratory CMV viral loads using laboratory-
developed NATs can vary significantly—especially at low
viral loads (from 2 log10 copies/mL to 4.3 log10 copies/
mL on the same specimen) and when testing was per-
formed prior to the development of WHO International
Calibration Standards in 2010 [34]. We expect that this
will have minimal impact on our results as we will use
any CMV antigenemia or DNAemia to define CMV
reactivation.
Discussion
This systematic review and meta-analysis will explore
the association between CMV reactivation, patient-
centered outcomes, and health resource utilization in
immunocompetent critically ill patients. Our results will
help to better define the burden of disease associated
with CMV reactivation. Indeed, evidence to date sug-
gests increased mortality in this patient population.
However, the relationship between CMV reactivation
and health resource utilization is less clear. Based on our
results, future study on the impact of CMV treatment or
prophylaxis on outcomes (including those other than
mortality) may be warranted.
Additional files
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Additional file 3: Data to be collected. (DOC 99.7 kb)
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